Mechanisms and management of cough in interstitial lung disease

References

• Lan NSH, Moore I, Lake F. Understanding cough in interstitial lung disease: a cross‐sectional study on the adequacy of treatment. Intern Med J. 2021;51(6):923–929. doi: 10.1111/imj.14837
   PubMed Web of Science ®Google Scholar
• Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010;6(1):1–7. doi: 10.1186/1745-9974-6-4
   PubMedGoogle Scholar
• Kamei J, Takaha Shi Y, Yoshikawa Y, et al. Involvement of P2X receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity. Eur J Pharmacol. 2005;528(1–3):158–161. doi: 10.1016/j.ejphar.2005.10.030
   PubMed Web of Science ®Google Scholar
• Cheng JZ, Wilcox PG, Glaspole I, et al. Cough is less common and less severe in systemic sclerosis-associate interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology. 2017;22(8):1592–1597. doi: 10.1111/resp.13084
   PubMed Web of Science ®Google Scholar
• Chung KF, McGarvey L, Song WJ, et al. Cough hypersensitivity and chronic cough. Nat Rev Dis Primers. 2022 Jun 30;8(1):45. doi: 10.1038/s41572-022-00370-w
   PubMedGoogle Scholar
• Key AL, Holt K, Hamilton A, et al. Objective cough frequency in idiopathic pulmonary fibrosis. Cough. 2010;6(1):4. doi: 10.1186/1745-9974-6-4
   PubMedGoogle Scholar
• Smith J, Owen E, Earis J, et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2006 Apr;117(4):831–5. Epub 2006 Feb 7. PMID: 166309412. doi: 10.1016/j.jaci.2005.09.055
   PubMed Web of Science ®Google Scholar
• Morice AH, Menon MS, Mulrennan SA, et al. Opiate therapy in chronic cough. Am J Respir Crit Care Med. 2007 Feb 15;175(4):312–5. Epub 2006 Nov 22. PMID: 17122382. doi: 10.1164/rccm.200607-892OC
   PubMed Web of Science ®Google Scholar
• Jeyakumar A, Brickman TM, Haben M. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. Laryngoscope. 2006 Dec;116(12):2108–12. PMID: 17146380. doi: 10.1097/01.mlg.0000244377.60334.e3
   PubMed Web of Science ®Google Scholar
• Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Nov 3;380(9853):1583–9. doi: 10.1016/S0140-6736(12)60776-4. Epub 2012 Aug 28. PMID: 22951084.
   PubMed Web of Science ®Google Scholar
• Lim KG, Rank MA, Hahn PY, et al. Long-term safety of nebulized lidocaine for adults with difficult-to-control chronic cough: a case series. Chest. 2013 Apr;143(4):1060–1065. PMID: 23238692. doi: 10.1378/chest.12-1533
   PubMed Web of Science ®Google Scholar
• Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015 Mar 28;385(9974):1198–205. doi: 10.1016/S0140-6736(14)61255-1. Epub 2014 Nov 25. PMID: 25467586.
   PubMed Web of Science ®Google Scholar
• Smith J, Allman D, Badri H, et al. The neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 Pilot study (VOLCANO-1). Chest. 2020 Jan;157(1):111–118. Epub 2019 Aug 14. PMID: 31421110. doi: 10.1016/j.chest.2019.08.001
   PubMed Web of Science ®Google Scholar
• Lutherer LO, Nugent KM, Schoettle BW, et al. Low-dose oral interferon possibly retards the progression of idiopathic pulmonary fibrosis and alleviates associated cough in some patients. (Letter) Thorax. 2011;66(5):446–446. doi: 10.1136/thx.2010.135947
   PubMed Web of Science ®Google Scholar
• Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012 Sep 18;157(6):398–406. doi: 10.7326/0003-4819-157-6-201209180-00003
   PubMed Web of Science ®Google Scholar
• Satia I, Badri H, Dockry R, et al. S91 S91 A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with idiopathic pulmonary fibrosis. Thorax. 2015;70(Suppl 3):A52.1–A52. doi: 10.1136/thoraxjnl-2015-207770.97
   Google Scholar
• Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017 Oct;5(10):806–815. doi: 10.1016/S2213-2600(17)30310-7
   PubMed Web of Science ®Google Scholar
• Van Manen MJG, Birring SS, Vancheri C, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017 Oct 19;50(4):1701157. doi: 10.1183/13993003.01157-2017
   PubMed Web of Science ®Google Scholar
• Guler SA, Clarenbach C, Brutsche M, et al. Azithromycin for the treatment of chronic cough in idiopathic pulmonary fibrosis: a randomized controlled crossover trial. Ann Am Thorac Soc. 2021 Dec;18(12):2018–2026.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Afzal AS, Smith JA, et al. Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with Gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial. Pulm Ther. 2021 Dec;7(2):471–486.
   PubMedGoogle Scholar
• Martinez FJ, Wijsenbeek MS, Raghu G, et al. Phase 2B study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: a multicenter, randomized, placebo-controlled study (SCENIC trial). Am J Respir Crit Care Med. 2022 May 1;205(9):1084–1092. PMID: 35050837. doi: 10.1164/rccm.202106-1485OC
   PubMed Web of Science ®Google Scholar
• Maher TM, Avram C, Bortey E, et al. Thomas Sciascia.Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. NEJM Evid. 2023;2(8):*. doi: 10.1056/EVIDoa2300083
   PubMedGoogle Scholar
• Zhe W, Spencer LG, Banya W, et al. Late breaking abstract - morphine sulfate for the treatment of cough in idiopathic pulmonary fibrosis the PAciFy cough randomized clinical trial. European Respiratory Journal Sep. 2023;62(suppl 67):OA4195. doi: 10.1183/13993003.congress-2023.OA4195
   Google Scholar
• Pratter MR, Brightling CE, Boulet LP, et al. An empiric integrative approach to the management of cough: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1 Suppl):222S–231S. doi: 10.1378/chest.129.1_suppl.222S
   PubMed Web of Science ®Google Scholar
• Chang AB, Lasserson TJ, Kiljander TO, et al. Systematic review and meta-analysis of randomized controlled trials of gastrooesophageal reflux interventions for chronic cough associated with gastrooesophageal reflux. BMJ. 2006;332(7532):11–17. doi: 10.1136/bmj.38677.559005.55
   PubMedGoogle Scholar
• Kahrilas PJ, Altman KW, Chang AB, et al. CHEST expert cough panel. Chronic cough due to Gastroesophageal Reflux in adults: CHEST guideline and expert panel report. Chest. 2016 Dec;150(6):1341–1360.
   PubMed Web of Science ®Google Scholar
• Prudon B, Birring SS, Vara DD, et al. Cough and glottic-stop reflex sensitivity in health and disease. Chest. 2005 Feb;127(2):550–7. PMID: 15705995. doi: 10.1378/chest.127.2.550
   PubMed Web of Science ®Google Scholar
• Ando A, Smallwood D, McMahon M, et al. Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control. Thorax. 2016 Apr;71(4):323–9. Epub 2016 Feb 9. PMID: 26860344. doi: 10.1136/thoraxjnl-2015-207425
   PubMed Web of Science ®Google Scholar
• Vertigan AE, Haines J, Slovarp L. An update on speech pathology management of chronic refractory cough. J Allergy Clin Immunol Pract. 2019;7(6):1756–1761. doi: 10.1016/j.jaip.2019.03.030
   PubMed Web of Science ®Google Scholar
• Vertigan AE, Theodoros DG, Gibson PG, et al. Efficacy of speech pathology management for chronic cough: a randomised placebo-controlled trial of treatment efficacy. Thorax. 2006;61(12):1065–1069. doi: 10.1136/thx.2006.064337
   PubMed Web of Science ®Google Scholar
• Chamberlain Mitchell SAF, Garrod R, Clark L, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017;72(2):129–136. doi: 10.1136/thoraxjnl-2016-208843
   PubMed Web of Science ®Google Scholar
• Vertigan AE, Kapela SL, Ryan NM, et al. Pregabalin and speech pathology combination therapy for refractory chronic cough: a randomized controlled trial. Chest. 2016 Mar;149(3):639–48. Epub 2016 Jan 12. PMID: 26447687. doi: 10.1378/chest.15-1271
   PubMed Web of Science ®Google Scholar
• Dhillon VK. Superior laryngeal nerve block for neurogenic cough: a case series. Laryngoscope Investig Otolaryngol. 2019 Jul 5;4(4):410–413.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011 Aug;16(6):969–75.
   PubMed Web of Science ®Google Scholar
• Saunders P, Wu Z, Fahy WA, et al. The burden and impact of cough in patients with idiopathic pulmonary fibrosis: an analysis of the prospective observational PROFILE study. Ann Am Thorac Soc. 2023 May 9;20(9):1267–1273. doi: 10.1513/AnnalsATS.202302-174OC
   PubMed Web of Science ®Google Scholar
• Scholand MB, Wolff R, Crossno PF, et al. Severity of cough in idiopathic pulmonary fibrosis is associated with MUC5 B genotype. Cough. 2014 Mar 25;10(1):3.
   PubMedGoogle Scholar
• Morice A, Dicpinigaitis P, McGarvey L, et al. Chronic cough: new insights and future prospects. Eur Respir Rev. 2021 Nov 30;30(162):210127. doi: 10.1183/16000617.0127-2021
   PubMed Web of Science ®Google Scholar
• Guo Y, Ying S, Zhao X, et al. Increased expression of lung TRPV1/TRPA1 in a cough model of bleomycin-induced pulmonary fibrosis in Guinea pigs. BMC Pulm Med. 2019 Feb 4;19(1):27. PMID: 30717786; PMCID: PMC6360795. doi: 10.1186/s12890-019-0792-z
   PubMedGoogle Scholar
• Jones RM, Hilldrup S, Hope-Gill BD, et al. Mechanical induction of cough in idiopathic pulmonary fibrosis. Cough. 2011 Apr 10;7(1):2.
   PubMedGoogle Scholar
• Hope-Gill B, Hilldrup S, Davies C, et al. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(8):995–1002. doi: 10.1164/rccm.200304-597OC
   PubMed Web of Science ®Google Scholar
• Okazaki A, Ohkura N, Fujimura M, et al. Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs. Pulm Pharmacol Ther. 2013;26(5):603–608. doi: 10.1016/j.pupt.2013.06.009
   PubMed Web of Science ®Google Scholar
• Prednisone, Azathioprine, and N -acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977. doi: 10.1056/NEJMoa1113354
   PubMed Web of Science ®Google Scholar
• Wakwaya Y, Ramdurai D, Swigris JJ. Managing cough in idiopathic pulmonary fibrosis. Chest. 2021 Nov;160(5):1774–1782.**. doi: 10.1016/j.chest.2021.05.071
   PubMed Web of Science ®Google Scholar
• Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020 Mar;8(3):304–320.
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63. doi: 10.1136/ard.2006.062901
   PubMed Web of Science ®Google Scholar
• Hu PQ, Fertig N, TA M Jr, et al. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 2003;48(5):1363–1373. doi: 10.1002/art.10977
   PubMedGoogle Scholar
• Theodore AC, Tseng CH, Li N, et al. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the scleroderma lung study. Chest. 2012 Sep;142(3):614–621. doi: 10.1378/chest.11-0801
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. SENSCIS trial investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019 Jun 27;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Volkmann ER, Tseng CH, et al. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II. Chest. 2017 Apr;151(4):813–820.
   PubMed Web of Science ®Google Scholar
• Karlsson JA. The role of capsaicin-sensitive C-fibre afferent nerves in the cough reflex. Pulm Pharmacol. 1996;9(5–6):315–321. doi: 10.1006/pulp.1996.0041
   PubMedGoogle Scholar
• Lalloo UG, Lim S, DuBois R, et al. Increased sensitivity of the cough reflex in progressive systemic sclerosis patients with interstitial lung disease. Eur Respir J. 1998;11(3):702–705. doi: 10.1183/09031936.98.11030702
   PubMed Web of Science ®Google Scholar
• Ando K, Motojima S, Doi T, et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir Invest. 2013;51(2):69–75. doi: 10.1016/j.resinv.2012.12.002
   PubMedGoogle Scholar
• Kowal-Bielecka O, Landewe R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8. doi: 10.1136/ard.2008.096677
   PubMed Web of Science ®Google Scholar
• Tanaka N, Kim J, Newell J, et al. Rheumatoid Arthritis–related Lung Diseases: CT Findings. Radiology. 2004;232(1):81–91. doi: 10.1148/radiol.2321030174
   PubMed Web of Science ®Google Scholar
• Gochuico BR. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008 Jan 28;168(2):159–166.
   PubMedGoogle Scholar
• Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004 Feb;50(2):380–386. doi: 10.1002/art.20018
   PubMed Web of Science ®Google Scholar
• Doyle TJ, Lee JS, Dellaripa PF, et al. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest. 2014 Mar 1;145(3):454–463. doi: 10.1378/chest.13-2408
   PubMed Web of Science ®Google Scholar
• Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir med. 2012 Jul;106(7):1040–1047. doi: 10.1016/j.rmed.2012.03.006
   PubMed Web of Science ®Google Scholar
• Murano E, Hosako-Naito Y, Tayama N, et al. Bamboo node: primary vocal fold lesions as evidence of autoimmune disease. J Voice. 2001;15(3):441–450. doi: 10.1016/S0892-1997(01)00044-3
   PubMed Web of Science ®Google Scholar
• Schnabel A, Dalhoff K, Bauerfeind S, et al. Sustained cough in methotrexate therapy for rheumatoid arthritis. Clin Rheumatol. 1996 May;15(3):277–82.
   PubMed Web of Science ®Google Scholar
• Shaw M, Collins BF, Ho LA, et al. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015 Mar;24(135):1–16.
   PubMedGoogle Scholar
• Duarte AC, Porter J, Leandro MJ. Bronchiectasis in rheumatoid arthritis. A clinical appraisial. Joint Bone Spine. 2020 Oct;87(5):419–424. doi: 10.1016/j.jbspin.2019.12.006
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009 May;337(5):329–35. doi: 10.1097/MAJ.0b013e31818d094b
   PubMed Web of Science ®Google Scholar
• Peno-Green L, Lluberas G, Kingsley T, et al. Lung injury linked to etanercept therapy. Chest. 2002 Nov;122(5):1858–60.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. British Society for Rheumatology Biologics Register. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010 Jun;69(6):1086–1091. doi: 10.1136/ard.2009.120626
   PubMed Web of Science ®Google Scholar
• Kreider M, Highland K. Pulmonary involvement in Sjögren syndrome. Semin Respir Crit Care Med. 2014;35(2):255–264. doi: 10.1055/s-0034-1371529
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Primary sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81(4):281–292. doi: 10.1097/00005792-200207000-00004
   PubMed Web of Science ®Google Scholar
• Mialon P, Barthélémy L, Sébert P, et al. A longitudinal study of lung impairment in patients with primary Sjögren’s syndrome. Clin Exp Rheumatol. 1997;15:349–54. 4
   PubMed Web of Science ®Google Scholar
• Papiris SA, Saetta M, Turato G, et al. CD4-positive T-lymphocytes infiltrate the bronchial mucosa of patients with Sjögren’s syndrome. Am J Respir Crit Care Med. 1997;156(2):637–641. doi: 10.1164/ajrccm.156.2.9610076
   PubMed Web of Science ®Google Scholar
• Gudbjörnsson B, Hedenström H, Stålenheim G, et al. Bronchial hyperresponsiveness to methacholine in patients with primary Sjogren’s syndrome. Ann Rheum Dis. 1991;50(1):36–40. doi: 10.1136/ard.50.1.36
   PubMed Web of Science ®Google Scholar
• Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren’s syndrome. Eur Respir Rev. 2016 Jun;25(140):110–23.
   PubMed Web of Science ®Google Scholar
• Kurasawa K, Nawata Y, Takabayashi K, et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol. 2002;129(3):541–548. doi: 10.1046/j.1365-2249.2002.01933.x
   PubMed Web of Science ®Google Scholar
• Lúdvíksdóttir D, Janson C, Björnsson E, et al. Different airway responsiveness profiles in atopic asthma, nonatopic asthma, and Sjögren’s syndrome.Allergy. 2000 ;55(3): 259–265. doi: 10.1034/j.1398-9995.2000.00252.x
   PubMed Web of Science ®Google Scholar
• Aerni MR, Vassallo R, Myers JL, et al. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir med. 2008;102(2):307–312. doi: 10.1016/j.rmed.2007.07.032
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the AutoImmune and rituximab registry. Ann Rheum Dis. 2013;72(6):1026–1031. doi: 10.1136/annrheumdis-2012-202293
   PubMed Web of Science ®Google Scholar
• Borie R, Schneider S, Debray M-P, et al. Severe chronic bronchiolitis as the presenting feature of primary Sjögren’s syndrome. Respir med. 2011;105(1):130–136. doi: 10.1016/j.rmed.2010.07.017
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS task force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology. 2015;54(12):2230–2238. doi: 10.1093/rheumatology/kev200
   PubMed Web of Science ®Google Scholar
• Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597–613. doi: 10.1016/j.jaad.2005.10.041
   PubMed Web of Science ®Google Scholar
• Vojinovic T, Cavazzana I, Ceruti P, et al. Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis. Clin Rev Allergy Immunol. 2021 Feb;60(1):87–94.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology. 2015;54(5):784–791. doi: 10.1093/rheumatology/keu385
   PubMed Web of Science ®Google Scholar
• Horiike Y, Suzuki Y, Fujisawa T, et al. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD. Rheumatology. 2019;58(12):2143–2152. doi: 10.1093/rheumatology/kez185
   PubMed Web of Science ®Google Scholar
• Brodeur TY, Robidoux TE, Weinstein JS, et al. IL-21 promotes pulmonary fibrosis through the induction of profibrotic CD8+ T cells. J Immunol. 2015;195(11):5251–5260. doi: 10.4049/jimmunol.1500777
   PubMed Web of Science ®Google Scholar
• Morisset J, Johnson C, Rich E, et al. Management of myositis-related interstitial lung disease. Chest. 2016;150(5):1118–1128. doi: 10.1016/j.chest.2016.04.007
   PubMed Web of Science ®Google Scholar
• Sinha A, Lee KK, Rafferty GF, et al. Predictors of objective cough frequency in pulmonary sarcoidosis. Eur Respir J. 2016;47(5):1461–1471. doi: 10.1183/13993003.01369-2015
   PubMed Web of Science ®Google Scholar
• Aryal S, Nathan SD. Contemporary optimized practice in the management of pulmonary sarcoidosis. Ther Adv Respir Dis. 2019;13:175346661986893. doi: 10.1177/1753466619868935
   Web of Science ®Google Scholar
• Sève P, Pacheco Y, Durupt F, et al. Sarcoidosis: A clinical overview from symptoms to diagnosis. Cells. 2021;10(4):766. doi: 10.3390/cells10040766
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Russell A-M, Jensen K, et al. Health-related quality of life (hrqol) in sarcoidosis. Diagnostics. 2021;11(6):1089. doi: 10.3390/diagnostics11061089
   Web of Science ®Google Scholar
• Tully T, Birring SS. Cough in sarcoidosis. Lung. 2015;194(1):21–24. doi: 10.1007/s00408-015-9799-2
   PubMed Web of Science ®Google Scholar
• Raj AA, Birring SS. Clinical assessment of chronic cough severity. Pulm Pharmacol Ther. 2007;20(4):334–337. doi: 10.1016/j.pupt.2006.10.002
   PubMed Web of Science ®Google Scholar
• Fujimura M, Kamio Y, Hashimoto T, et al. Cough receptor sensitivityand bronchial responsiveness in patients with only chronic nonproductive cough: in view of effect of bronchodilator therapy. J Asthma. 1994;31(6):463–472. doi: 10.3109/02770909409089488
   PubMed Web of Science ®Google Scholar
• Young LM, Good N, Milne D, et al. The prevalence and predictors of airway hyperresponsiveness in sarcoidosis. Respirology. 2012;17(4):653–659. doi: 10.1111/j.1440-1843.2012.02137.x
   PubMed Web of Science ®Google Scholar
• Xin-Min D, Qin-Zhi X, Yun-You D, et al. Impact of tracheal mucosa involvement on clinical characteristics of sarcoidosis. Southern Med J. 2011;104(5):315–318. doi: 10.1097/SMJ.0b013e318213ec03
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE, Tami T. Upper airway.4: sarcoidosis of the upper respiratory tract (SURT). Thorax. 2010;65(2):181–186. doi: 10.1136/thx.2008.112896
   PubMed Web of Science ®Google Scholar
• Jones RM, Dawson A, Jenkins GH, et al. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J. 2009;34(2):517–520. doi: 10.1183/09031936.00044609
   PubMed Web of Science ®Google Scholar
• Alon EE, Ekbom DC. Neurosarcoidosis affecting the vagus nerve. Ann Otol Rhinol Laryngol. 2010;119(9):641–645. doi: 10.1177/000348941011900913
   PubMed Web of Science ®Google Scholar
• Richeldi L, Varone F, Bergna M, et al. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev. 2018;27(150):180074. doi: 10.1183/16000617.0074-2018
   PubMed Web of Science ®Google Scholar
• Erkkilä S, Fröseth B, Hellström PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis. 1988 Sep;5(2):106–110.
   PubMedGoogle Scholar
• Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis. 1993 Mar;10(1):56–61.
   PubMedGoogle Scholar
• Milman N, Graudal N, Grode G, et al. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med. 1994 Sep;236(3):285–90.
   PubMed Web of Science ®Google Scholar
• Birring SS, Kavanagh JE, Irwin RS, et al. Treatment of interstitial lung disease associated cough: CHEST guideline and expert panel report. Chest. 2018 Oct;154(4):904–917. Collaborators. 10.1016/j.chest.2018.06.038
   PubMed Web of Science ®Google Scholar
• Paramothayam S, Jones PW. Corticosteroid therapy in sarcoidosis: s systemic review. JAMA. 2002;287(10):1301–1307. doi: 10.1001/jama.287.10.1301
   PubMed Web of Science ®Google Scholar
• Hansell DM, Milne DG, Wilsher ML, et al. Pulmonary sarcoidosis: morphologic associations of airflow obstruction at thin-section CT. Radiology. 1998 Dec;209(3):697–704.
   PubMed Web of Science ®Google Scholar
• Harrison BD, Shaylor JM, Stokes TC, et al. Airflow limitation in sarcoidosis–a study of pulmonary function in 107 patients with newly diagnosed disease. Respir med. 1991 Jan;85(1):59–64. doi: 10.1016/S0954-6111(06)80211-8
   PubMed Web of Science ®Google Scholar
• Fraser SD, Thackray-Nocera S, Shepherd M, et al. Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial. ERJ Open Res. 2020 Nov 10;6(4):00534–2020. doi: 10.1183/23120541.00534-2020
   PubMedGoogle Scholar
• Watts MM, Grammer LC. Hypersensitivity pneumonitis. Allergy Asthma Proc. 2019 Nov 1;40(6):425–428.
   PubMed Web of Science ®Google Scholar
• Cheng JZ, Wilcox PG, Glaspole I, et al. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases. Respirology. 2017;22(8):1592–1597. doi: 10.1111/resp.13084
   PubMed Web of Science ®Google Scholar
• Sato R, Handa T, Matsumoto H, et al. Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study. BMC Pulm Med. 2019a;19(1). doi: 10.1186/s12890-019-1012-6
   Web of Science ®Google Scholar
• Blatman KH, Grammer LC. Chapter 19: hypersensitivity pneumonitis. Allergy Asthma Proc. 2012 May;33(Suppl 3):64–66. doi: 10.2500/aap.2012.33.3552
   PubMedGoogle Scholar
• Brown KK. Chronic cough due to chronic interstitial pulmonary diseases.Chest. Chest. 2006;129(1):180S–185S. doi: 10.1378/chest.129.1_suppl.180S
   PubMed Web of Science ®Google Scholar
• Franquet T, Hansell DM, Senbanjo T, et al. Lung cysts in subacute hypersensitivity pneumonitis. J Comput Assist Tomogr. 2003;27(4):475–478. doi: 10.1097/00004728-200307000-00003
   PubMed Web of Science ®Google Scholar
• Baqir M, White D, Ryu JH. Emphysematous changes in hypersensitivity pneumonitis: a retrospective analysis of 12 patients. Respir Med Case Rep. 2018 Mar 22;24:25–29. doi: 10.1016/j.rmcr.2018.03.012
   PubMed Web of Science ®Google Scholar
• Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer’s lung. Am Rev Respir Dis. 1992;145(1):3–5. doi: 10.1164/ajrccm/145.1.3
   PubMed Web of Science ®Google Scholar
• Ojanguren I, Cruz MJ, Villar A, et al. Utility of exhaled nitric oxide fraction for the diagnosis of hypersensitivity pneumonitis. Lung. 2016 Feb;194(1):75–80. doi: 10.1007/s00408-015-9824-5
   PubMed Web of Science ®Google Scholar
• Varney VA, Quirke G, Witwit A, et al. Longstanding hypersensitivity pneumonitis and its response to roflumilast: a review of its likely immunological effects. Respir Med Case Rep. 2022 Jul 20;39:101701. doi: 10.1016/j.rmcr.2022.101701
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2):85–118. doi: 10.1016/S0162-3109(00)00188-0
   PubMedGoogle Scholar
• Leone PM, Richeldi L. Current diagnosis and management of hypersensitivity pneumonitis. Tuberc Respir Dis (Seoul). 2020 Apr;83(2):122–131. doi: 10.4046/trd.2020.0012
   PubMed Web of Science ®Google Scholar
• Mehta P, Rosas IO, Singer M. Understanding post-COVID-19 interstitial lung disease (ILD): a new fibroinflammatory disease entity. Intensive care Med. 2022 Dec;48(12):1803–1806. doi: 10.1007/s00134-022-06877-w
   PubMed Web of Science ®Google Scholar
• Lorent N, Vande Weygaerde Y, Claeys E, et al. Prospective longitudinal evaluation of hospitalized COVID-19 survivors 3 and 12 months after discharge. ERJ Open Res. 2022;8(2):00004–2022. doi: 10.1183/23120541.00004-2022
   PubMedGoogle Scholar
• McDonald LT. Healing after COVID-19: Are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2021;320(2):L257–65. doi: 10.1152/ajplung.00238.2020
   PubMed Web of Science ®Google Scholar
• Dicpinigaitis PV, Spinner L, Santhyadka G, et al. Effect of tiotropium on cough reflex sensitivity in acute viral cough. Lung. 2008;186(6):369–374. doi: 10.1007/s00408-008-9114-6
   PubMed Web of Science ®Google Scholar
• Shiers S, Ray PR, Wangzhou A. ACE2 and SCARF expression in human dorsal root ganglion nociceptors: Implications for SARS-CoV-2 virus neurological effects. Pain. 2020;161(11):2494–2501. doi: 10.1097/j.pain.0000000000002051
   PubMed Web of Science ®Google Scholar
• Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021 May;18(5):799–806. doi: 10.1513/AnnalsATS.202008-1002OC
   PubMed Web of Science ®Google Scholar
• Dhooria S, Chaudhary S, Sehgal IS, et al. High-dose versus low-dose prednisolone in symptomatic patients with post-COVID-19 diffuse parenchymal lung abnormalities: an open-label, randomised trial (the COLDSTER trial). Eur Respir J. 2022;59(2):2102930. doi: 10.1183/13993003.02930-2021
   PubMed Web of Science ®Google Scholar
• Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020 May;58(3):155–168.
   PubMed Web of Science ®Google Scholar